Partial cell reprogramming is a promising approach to rejuvenate cells and tissues by reversing age-related changes. This method involves temporarily reprogramming cells to a pluripotent state, which can restore their physiological functions and reduce aging markers. Recent studies have shown that partial reprogramming can rejuvenate human muscle stem cells, improve the aging mouse transcriptome and metabolome, and reverse the epigenetic clock in vitro. It has also been shown to extend the lifespan of aged mice and restore visual function. However, the process must be carefully controlled to avoid unintended consequences such as teratoma formation and genomic instability. Partial reprogramming can be achieved through various methods, including the use of Yamanaka factors or chemical cocktails. While Yamanaka factors are effective, chemical reprogramming offers a non-genetic alternative that may be easier to deliver. Both approaches have shown potential in rejuvenating cells, but they also raise safety concerns, particularly regarding the risk of tumorigenesis and the long-term effects on tissue function. The effectiveness of partial reprogramming varies across different tissues, and the process must be tailored to the specific needs of each tissue type. For example, while partial reprogramming can rejuvenate muscle cells, it may not be as effective for post-mitotic tissues like the heart. Additionally, the rejuvenation process may not fully reverse all aspects of aging, and the distinction between rejuvenation and dedifferentiation remains a topic of debate. The use of epigenetic clocks to measure biological age has provided valuable insights into the effects of partial reprogramming. However, these clocks may not fully capture the complexity of aging and rejuvenation, and further research is needed to develop more accurate biomarkers. The safety and efficacy of partial reprogramming must be thoroughly evaluated, particularly in the context of long-term therapeutic applications. In conclusion, partial cell reprogramming holds significant potential for treating age-related diseases and extending lifespan. However, further research is needed to understand the underlying mechanisms, optimize the process, and ensure its safety and effectiveness. The development of targeted therapies and the refinement of biomarkers will be crucial for translating these findings into clinical applications.Partial cell reprogramming is a promising approach to rejuvenate cells and tissues by reversing age-related changes. This method involves temporarily reprogramming cells to a pluripotent state, which can restore their physiological functions and reduce aging markers. Recent studies have shown that partial reprogramming can rejuvenate human muscle stem cells, improve the aging mouse transcriptome and metabolome, and reverse the epigenetic clock in vitro. It has also been shown to extend the lifespan of aged mice and restore visual function. However, the process must be carefully controlled to avoid unintended consequences such as teratoma formation and genomic instability. Partial reprogramming can be achieved through various methods, including the use of Yamanaka factors or chemical cocktails. While Yamanaka factors are effective, chemical reprogramming offers a non-genetic alternative that may be easier to deliver. Both approaches have shown potential in rejuvenating cells, but they also raise safety concerns, particularly regarding the risk of tumorigenesis and the long-term effects on tissue function. The effectiveness of partial reprogramming varies across different tissues, and the process must be tailored to the specific needs of each tissue type. For example, while partial reprogramming can rejuvenate muscle cells, it may not be as effective for post-mitotic tissues like the heart. Additionally, the rejuvenation process may not fully reverse all aspects of aging, and the distinction between rejuvenation and dedifferentiation remains a topic of debate. The use of epigenetic clocks to measure biological age has provided valuable insights into the effects of partial reprogramming. However, these clocks may not fully capture the complexity of aging and rejuvenation, and further research is needed to develop more accurate biomarkers. The safety and efficacy of partial reprogramming must be thoroughly evaluated, particularly in the context of long-term therapeutic applications. In conclusion, partial cell reprogramming holds significant potential for treating age-related diseases and extending lifespan. However, further research is needed to understand the underlying mechanisms, optimize the process, and ensure its safety and effectiveness. The development of targeted therapies and the refinement of biomarkers will be crucial for translating these findings into clinical applications.